134 related articles for article (PubMed ID: 2297697)
1. Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody.
Stewart JS; Sivolapenko GB; Hird V; Davies KA; Walport M; Ritter MA; Epenetos AA
Cancer Res; 1990 Feb; 50(3):563-7. PubMed ID: 2297697
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
4. A study of in vivo immune complex formation and clearance in man.
Davies KA; Hird V; Stewart S; Sivolapenko GB; Jose P; Epenetos AA; Walport MJ
J Immunol; 1990 Jun; 144(12):4613-20. PubMed ID: 2141040
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
6. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
7. Biological considerations for radioimmunotherapy.
Sharkey RM; Blumenthal RD; Hansen HJ; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):964s-969s. PubMed ID: 2297750
[TBL] [Abstract][Full Text] [Related]
8. Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule.
Ceriani RL; Blank EW
Cancer Res; 1988 Aug; 48(16):4664-72. PubMed ID: 3396015
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
10. Use of iodine-131-labeled anti-immune response-associated monoclonal antibody as preparative regimen prior to bone marrow transplantation: initial dosimetry.
Appelbaum FR; Badger CC; Deeg HJ; Nelp WB; Storb R
NCI Monogr; 1987; (3):67-71. PubMed ID: 3547145
[TBL] [Abstract][Full Text] [Related]
11. Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody.
Badger CC; Krohn KA; Peterson AV; Shulman H; Bernstein ID
Cancer Res; 1985 Apr; 45(4):1536-44. PubMed ID: 3978621
[TBL] [Abstract][Full Text] [Related]
12. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
14. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
Siegel JA; Pawlyk DA; Lee RE; Sasso NL; Horowitz JA; Sharkey RM; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens.
Sharkey RM; Gold DV; Aninipot R; Vagg R; Ballance C; Newman ES; Ostella F; Hansen HJ; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):828s-834s. PubMed ID: 2297729
[TBL] [Abstract][Full Text] [Related]
16. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Schroff RW; Foon KA; Beatty SM; Oldham RK; Morgan AC
Cancer Res; 1985 Feb; 45(2):879-85. PubMed ID: 3871353
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.
Sharkey RM; Pykett MJ; Siegel JA; Alger EA; Primus FJ; Goldenberg DM
Cancer Res; 1987 Nov; 47(21):5672-7. PubMed ID: 3664474
[TBL] [Abstract][Full Text] [Related]
18. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
[TBL] [Abstract][Full Text] [Related]
19. In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients.
Sakahara H; Reynolds JC; Carrasquillo JA; Lora ME; Maloney PJ; Lotze MT; Larson SM; Neumann RD
J Nucl Med; 1989 Aug; 30(8):1311-7. PubMed ID: 2754487
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.
Khazaeli MB; Saleh MN; Liu TP; Meredith RF; Wheeler RH; Baker TS; King D; Secher D; Allen L; Rogers K
Cancer Res; 1991 Oct; 51(20):5461-6. PubMed ID: 1913665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
